1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou), Inc. Class H

HHKEX:2500
1.03
HKD
+0.02
(+1.98%)
1.05BMarket Cap
Apr 01Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.05
0.29
0.75
0.67
0.95
0.93
1.12
1.08
0.7
- -
Basic EPS, GAAP
-0.4
-0.77
-1.22
-0.44
-0.85
-2.42
-1.61
-1.63
-0.93
- -
Free Cash Flow per Basic Share
-0.26
-0.45
-1.05
-0.88
-1.37
-2.07
-1.99
-0.04
-0.76
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.18
1.18
7.51
9.02
10.31
8.18
6.62
5.01
4
4
Tangible Book Value per Share
0.12
-0.51
5.85
7.28
8.43
3.98
3.05
1.65
0.79
0.79
Basic Weighted Avg Shares
393
393
311
409
439
438
438
438
438
438
Sales/Revenue/Turnover
18
115
233
276
416
406
491
471
307
- -
Operating Margin (%)
-847.18
-255.3
-136.69
-53.92
-65.4
-156.2
-116.22
-73.61
-106.72
- -
Depreciation Expense
6
10
29
38
52
112
125
111
97
- -
Net Income, GAAP
-157
-300
-381
-182
-374
-1,058
-704
-714
-408
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-861.77
-260.45
-163.21
-65.93
-89.85
-260.22
-143.22
-151.71
-132.89
- -
Working Capital
26
-205
2,336
2,955
3,231
1,977
803
441
426
426
LT Debt
4
15
17
22
48
654
331
313
21
21
Total Equity
81
470
3,046
3,857
4,632
3,631
2,919
2,211
1,763
1,763
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-112.55
-21.76
-5.31
-8.94
-25.94
-21.56
-27.84
-20.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
56
202
41
LT Borrowings
265
258
- -
LT Finance Leases
48
33
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
441
441
441
Market Capitalization
- -
1,038
943

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
802
733
667
Cash, Cash Equivalents & STI
306
293
264
Accounts Receivable, Net
199
138
99
Inventories
98
104
97
Total Current Liabilities
362
403
241
Payables & Accruals
- -
- -
- -
ST Debt
56
202
41
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.13%
-20.28%
Free Cash Flow
- -
355.96%
1,764.03%
Net Income, GAAP
- -
42.7%
-42.92%
Sales/Revenue/Turnover
- -
6.05%
-34.84%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
491
2024
- -
- -
471
2025
- -
- -
307

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.61
2024
- -
- -
-1.63
2025
- -
- -
-0.93

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hou-Sen Lim
Full Time Employees
560
Sector
Health technology
Industry
Medical specialties
Address
No. 88, Jiangling Road Wanchai ZH China 310051
IPO Date
Dec 10, 2019
Website
venusmedtech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Venus Medtech (Hangzhou) Inc. is a prominent entity in the development and global commercialization of transcatheter medical devices for structural heart conditions. The company's innovative portfolio includes several commercially available solutions, such as the VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe systems designed for transcatheter aortic valve replacement (TAVR) to address severe aortic stenosis. Furthermore, its VenusP-Valve, a unique self-expanding transcatheter pulmonary valve replacement (TPVR) system, is utilized for managing pulmonary regurgitation, having achieved significant international market penetration across Europe and other regions. The company also offers essential procedural accessories like expandable catheter sheaths and balloon catheters. Beyond its marketed offerings, Venus Medtech maintains a robust pipeline of next-generation therapies. This includes advanced TAVR product candidates such as Venus-Vitae and Venus-PowerX, both dry-valve systems currently advancing through pivotal clinical trials. The innovative Cardiovalve platform is under clinical investigation for transcatheter mitral and tricuspid valve replacement (TMVR and TTVR), with studies progressing across multiple international centers. Additionally, the company is at the forefront of developing the Liwen RF ablation system for treating hypertrophic cardiomyopathy and renal denervation solutions for hypertension management. Established in 2009 and based in Hangzhou, People's Republic of China, Venus Medtech continues to expand its global footprint, with international sales contributing a growing portion of its revenue and its products available in numerous markets worldwide. The firm's commitment to innovation is underlined by its extensive intellectual property portfolio and recent recognition for high-value patent cultivation. A strategic decision in November 2025 to sell an industrial park property aims to enhance financial flexibility and sharpen focus on core heart valve technologies.